Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
8.77
+0.44 (5.28%)
May 12, 2025, 4:00 PM - Market closed
Xencor Revenue
Xencor had revenue of $32.73M in the quarter ending March 31, 2025, with 104.61% growth. This brings the company's revenue in the last twelve months to $127.23M, down -25.88% year-over-year. In the year 2024, Xencor had annual revenue of $110.49M, down -36.72%.
Revenue (ttm)
$127.23M
Revenue Growth
-25.88%
P/S Ratio
4.70
Revenue / Employee
$508,912
Employees
250
Market Cap
624.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 110.49M | -64.12M | -36.72% |
Dec 31, 2023 | 174.62M | 10.04M | 6.10% |
Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
XNCR News
- 5 days ago - Xencor Reports First Quarter 2025 Financial Results - Business Wire
- 13 days ago - Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease - Business Wire
- 2 months ago - Xencor Appoints Todd Simpson to Board of Directors - Business Wire
- 2 months ago - Xencor Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 2 months ago - 20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset' - Market Watch
- 5 months ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 6 months ago - Xencor: Plamotamab NHL Data Leads To RA Program Advancement - Seeking Alpha
- 6 months ago - Xencor Reports Third Quarter 2024 Financial Results - Business Wire